» Articles » PMID: 19794311

Quality of Life in Cirrhosis is Related to Potentially Treatable Factors

Overview
Specialty Gastroenterology
Date 2009 Oct 2
PMID 19794311
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Improvement of prognosis and availability of diverse therapeutic options for complications of advanced liver disease highlight the importance of health-related quality of life (HRQOL) in cirrhosis. The aim of this study was to identify factors that influence HRQOL and may be potentially treatable in patients with cirrhosis.

Methods: HRQOL was measured in 212 outpatients with cirrhosis using a generic questionnaire (Medical Outcomes Study Form, SF-36) and a liver-specific questionnaire (Chronic Liver Disease Questionnaire, CLDQ). All patients underwent a systematic clinical and neuropsychological assessment. Independent factors associated with poor HRQOL were identified by multiple linear regression.

Results: HRQOL scores exhibited by patients were: global CLDQ: 4.8+/-1.2; Physical Component Score of SF-36: 38.5+/-10.7; Mental Component Score of SF-36: 45.3+/-14.3. The independent variables for global CLDQ were female sex, nonalcoholic etiology, current ascites, and a decrease in albumin (R = 0.22). For Physical Component Score of SF-36, the independent variables were prior hepatic encephalopathy, current ascites, and a decrease in hemoglobin (R = 0.22). For Mental Component Score of SF-36, the independent variables were nonalcoholic etiology, the Grooved Pegboard test, and a decrease in hemoglobin (R = 0.14).

Conclusion: Several clinical variables, potentially treatable, may alter particular aspects of HRQOL. Correction of ascites, hypoalbuminemia, minimal hepatic encephalopathy, and anemia may cause a positive impact on HRQOL of patients with cirrhosis.

Citing Articles

Predictors of survival in autoimmune liver disease overlap syndromes.

Jayabalan D, Huang Y, Calzadilla-Bertot L, Janjua M, De Boer B, Joseph J World J Hepatol. 2024; 16(9):1269-1277.

PMID: 39351512 PMC: 11438591. DOI: 10.4254/wjh.v16.i9.1269.


Palliative care in terminally ill advanced chronic liver disease patients.

Pomej K, Masel E, Kreye G Wien Klin Wochenschr. 2024; .

PMID: 39254776 DOI: 10.1007/s00508-024-02436-z.


The influence of muscle performance and fatigue on prognosis in patients with compensated liver disease.

Ekerfors U, Simren M, Marschall H, Demir D, Josefsson A BMC Gastroenterol. 2023; 23(1):302.

PMID: 37674115 PMC: 10483859. DOI: 10.1186/s12876-023-02885-2.


Comparison of the quality of life of patients with liver cirrhosis before and during the COVID-19 lockdown in Slovakia.

Skladany L, Liska D, Liptakova E, Tapajcikova T, Vnencakova J, Koller T Sci Rep. 2023; 13(1):2463.

PMID: 36774367 PMC: 9918821. DOI: 10.1038/s41598-023-29510-2.


Palliative long-term abdominal drains for the management of refractory ascites due to cirrhosis: a consensus document.

Macken L, Corrigan M, Prentice W, Finlay F, McDonagh J, Rajoriya N Frontline Gastroenterol. 2022; 13(e1):e116-e125.

PMID: 35812034 PMC: 9234735. DOI: 10.1136/flgastro-2022-102128.